The ERASE study - should every patient with acute coronary syndrome receive statin? Effects of HMG-CoA inhibitors on atherosclerotic plaque in acute coronary syndrome Review article
Article Sidebar
Published:
Apr 13, 2010
Keywords:
statyny, ostry zespół wieńcowy, blaszka miażdżycowa
Main Article Content
Abstract
Beneficial effects of statin therapy on reduction in death and myocardial infarction number were confirmed in both patients with stable angina pectoris and patients with acute coronary syndrome. Studies using intravascular ultrasonography demonstrated that intensive statin therapy reduces atherosclerotic plaque volume independently of initial cholesterol level. In 2009 ERASE study analysis came out where reduction of atherosclerotic plaque volume in ACS patients was already observed 6±1week after statin therapy began. Despite limitations of aforementioned analysis ERASE study results vindicate early HMG-CoA inhibitor treatment as soon as possible after ACS episode.
Article Details
How to Cite
Kornacewicz-Jach, Z., Czechowska, M., & Kossuth, I. (2010). The ERASE study - should every patient with acute coronary syndrome receive statin? Effects of HMG-CoA inhibitors on atherosclerotic plaque in acute coronary syndrome. Medycyna Faktow (J EBM), 3(1(6), 36-42. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2613
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 19(344): 1383-1389.
2. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998; 339: 1349-1357.
3. Goldberg R.B., Mellies M.J., Sacks F.M. et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial: the CARE Investigators. Circulation 1998; 98: 2513-2519.
4. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
5. Nissen S.E.: Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis With Aggressive Lipid Lowering (REVERSAL) trial. Am. J. Med. 2005; 118: 22S-27S.
6. Nissen S.E., Nicholls S.J., Sipahi I. et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-1565.
7. Okazaki S., Yokoyama T., Miyauchi K. et al.: Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
8. Hiro T., Kimura T., Morimoto T. et al.: Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome A Multicenter Randomized Trial Evaluated by Volumetric Intravascular Ultrasound Using Pitavastatin Versus Atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] Study). J. Am. Coll. Cardiol. 2009; 54: 293-302.
9. Rodés-Cabau J., Tardif J.C., Cossette M. et al.: Acute Effects of Statin Therapy on Coronary Atherosclerosis Following an Acute Coronary Syndrome. Am. J. Cardiol. 2009; 104: 750-757.
10. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
11. Ray K.K., Cannon C.P., McCabe C.H. et al.: Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: result from the PROVE IT – TIMI 22 trial. J. Am. Coll. Cardiol. 2005; 46: 405-410.
12. Cannon C.P., Braunwald E., McCabe C.H. et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004; 350: 1495-1504.
13. de Lemos J.A., Blazing M.A., Wiviott S.D. et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-1316.
14. Crisby M., Nordin-Fredriksson G., Shah P.K. et al.: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
15. Kinlay S., Rifai N., Libby P., Ganz P.: Effect of atorvastatin on C-reactive protein in patient with acute coronary syndrome: a substudy of the MIRACL Trial. J. Am. Coll. Cardiol. 2002; 39 (Suppl A): 304A.
2. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998; 339: 1349-1357.
3. Goldberg R.B., Mellies M.J., Sacks F.M. et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial: the CARE Investigators. Circulation 1998; 98: 2513-2519.
4. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
5. Nissen S.E.: Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis With Aggressive Lipid Lowering (REVERSAL) trial. Am. J. Med. 2005; 118: 22S-27S.
6. Nissen S.E., Nicholls S.J., Sipahi I. et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-1565.
7. Okazaki S., Yokoyama T., Miyauchi K. et al.: Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
8. Hiro T., Kimura T., Morimoto T. et al.: Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome A Multicenter Randomized Trial Evaluated by Volumetric Intravascular Ultrasound Using Pitavastatin Versus Atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] Study). J. Am. Coll. Cardiol. 2009; 54: 293-302.
9. Rodés-Cabau J., Tardif J.C., Cossette M. et al.: Acute Effects of Statin Therapy on Coronary Atherosclerosis Following an Acute Coronary Syndrome. Am. J. Cardiol. 2009; 104: 750-757.
10. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
11. Ray K.K., Cannon C.P., McCabe C.H. et al.: Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: result from the PROVE IT – TIMI 22 trial. J. Am. Coll. Cardiol. 2005; 46: 405-410.
12. Cannon C.P., Braunwald E., McCabe C.H. et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004; 350: 1495-1504.
13. de Lemos J.A., Blazing M.A., Wiviott S.D. et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-1316.
14. Crisby M., Nordin-Fredriksson G., Shah P.K. et al.: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
15. Kinlay S., Rifai N., Libby P., Ganz P.: Effect of atorvastatin on C-reactive protein in patient with acute coronary syndrome: a substudy of the MIRACL Trial. J. Am. Coll. Cardiol. 2002; 39 (Suppl A): 304A.